Cargando…

Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening

PURPOSE: Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitagawa, Yasuhide, Mizokami, Atsushi, Namiki, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society (APPS) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814114/
https://www.ncbi.nlm.nih.gov/pubmed/24223404
http://dx.doi.org/10.12954/PI.12017
_version_ 1782289209156960256
author Kitagawa, Yasuhide
Mizokami, Atsushi
Namiki, Mikio
author_facet Kitagawa, Yasuhide
Mizokami, Atsushi
Namiki, Mikio
author_sort Kitagawa, Yasuhide
collection PubMed
description PURPOSE: Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate cancer patients aged 55 to 69 years old in our institution. METHODS: Between 2000 and 2007, 162 cases of prostate cancer in patients aged 55 to 69 years old were newly diagnosed. The study population was divided into 119 cases with high PSA without symptoms, 36 cases with urological symptoms, and 7 cases with systemic symptoms. We analyzed the clinical courses of the patients in each group. RESULTS: The rate of localized disease was significantly higher in the PSA testing group than in the other groups. The median serum PSA levels were 1,600 ng/mL in the systemic symptom group, 13.3 ng/mL in the urological symptom group, and 7.1 ng/mL in the PSA testing group. The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups. CONCLUSIONS: The rate of prostate cancer patients diagnosed by PSA testing was relatively high in our institution. These patients have better prognosis than those with symptoms.
format Online
Article
Text
id pubmed-3814114
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Asian Pacific Prostate Society (APPS)
record_format MEDLINE/PubMed
spelling pubmed-38141142013-11-12 Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening Kitagawa, Yasuhide Mizokami, Atsushi Namiki, Mikio Prostate Int Original Article PURPOSE: Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate cancer patients aged 55 to 69 years old in our institution. METHODS: Between 2000 and 2007, 162 cases of prostate cancer in patients aged 55 to 69 years old were newly diagnosed. The study population was divided into 119 cases with high PSA without symptoms, 36 cases with urological symptoms, and 7 cases with systemic symptoms. We analyzed the clinical courses of the patients in each group. RESULTS: The rate of localized disease was significantly higher in the PSA testing group than in the other groups. The median serum PSA levels were 1,600 ng/mL in the systemic symptom group, 13.3 ng/mL in the urological symptom group, and 7.1 ng/mL in the PSA testing group. The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups. CONCLUSIONS: The rate of prostate cancer patients diagnosed by PSA testing was relatively high in our institution. These patients have better prognosis than those with symptoms. Asian Pacific Prostate Society (APPS) 2013 2013-06-30 /pmc/articles/PMC3814114/ /pubmed/24223404 http://dx.doi.org/10.12954/PI.12017 Text en Copyright © 2013 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kitagawa, Yasuhide
Mizokami, Atsushi
Namiki, Mikio
Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
title Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
title_full Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
title_fullStr Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
title_full_unstemmed Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
title_short Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
title_sort trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814114/
https://www.ncbi.nlm.nih.gov/pubmed/24223404
http://dx.doi.org/10.12954/PI.12017
work_keys_str_mv AT kitagawayasuhide trendsofclinicalsymptomsandprognosisofmiddleagedprostatecancerpatientsafterinstigationofprostatespecificantigenbasedpopulationscreening
AT mizokamiatsushi trendsofclinicalsymptomsandprognosisofmiddleagedprostatecancerpatientsafterinstigationofprostatespecificantigenbasedpopulationscreening
AT namikimikio trendsofclinicalsymptomsandprognosisofmiddleagedprostatecancerpatientsafterinstigationofprostatespecificantigenbasedpopulationscreening